BeOne Medicines (ONC) FCF Margin (2015 - 2026)

BeOne Medicines (ONC) has reported FCF Margin for 12 consecutive years, with 25.68% the latest figure, recorded in Q2 2026.

• On a quarterly basis, FCF Margin rose 869.0% year-over-year to 25.68% in Q2 2026; TTM through Jun 2026 was 21.7%, a 1634.0% increase from a year earlier, with the FY2025 full-year figure at 17.63%, up 3425.0% from the prior year.
• FCF Margin was 25.68% for Q2 2026 at BeOne Medicines, up from 10.45% in the prior quarter.
• Over five years, FCF Margin peaked at 25.68% in Q2 2026 and troughed at 172.99% in Q3 2022.
• A 5-year average of 44.37% and a median of 26.17% in 2023 frame the typical range for FCF Margin.
• The widest YoY moves for FCF Margin: up 18507 bps in 2022, down 11126 bps in 2022.
• Over 5 years, FCF Margin stood at 115.64% in 2022, then soared by 48 bps to 59.68% in 2023, then soared by 97 bps to 1.54% in 2024, then surged by 1751 bps to 25.35% in 2025, then advanced by 1 bps to 25.68% in 2026.
• The last three FCF Margin figures came in at 25.68% (Q2 2026), 10.45% (Q1 2026), and 25.35% (Q4 2025), per Business Quant data.